Study shows booster dose of Covaxin has neutralising effect on Omicron, Delta variants, says Bharat Biotech
The study conducted at Emory University demonstrated that subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series have witnessed neutralising of the SARS-CoV-2 Omicron and Delta variants, the vaccine major said in a statement.
Earlier studies had demonstrated the neutralising potential of Covaxin against other SARS-CoV-2 variants -- Alpha, Beta, Delta, Zeta and Kappa, it added.
Citing the study results, Bharat Biotech noted that more than 90 per cent of all individuals boosted with Covaxin showed neutralising antibodies.
"As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern. Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants.
"These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations," Emory Vaccine Center Assistant Professor Mehul Suthar, who led the laboratory analysis, noted.
Bharat Biotech Chairman and Managing Director
"The positive neutralization responses against the Omicron and Delta variants, validates our hypothesis of a multi-epitope vaccine generating both humoral and cell mediated immune responses.
"Our goals of developing a global vaccine against COVID-19 have been achieved with the use of Covaxin as a universal vaccine for adults and children," he added.
The study conducted at Emory Vaccine Center in Atlanta was sponsored by Ocugen, Inc. Bharat Biotech provided the sera of the subjects from the Phase 2 study.
TCS vs Infosys vs Wipro Q3 results – here’s how India’s three IT giants stack up against each other
Tata Motors, TCS, Paytm, and other hot stocks on January 13
Popular on BI
- Fintech unicorn CRED to acquire SaaS startup CreditVidya
- Jio Haptik and CASHe partner to deliver instant credit lines on Whatsapp
- Dharmaj Crop Guard IPO subscribed 5.97 times on day 2
- Recent IPO successes could lead to recovery in the primary market: E&Y
- Capex cycle to touch ₹21 lakh crore in FY23, but there's a catch